INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

Their core work

IRIS is the international clinical research arm of Servier, one of France's largest independent pharmaceutical companies. They contribute pharmaceutical industry expertise to large-scale public-private research initiatives, particularly in drug safety assessment, clinical trial design, and health data standardization. Their involvement spans oncology, cardiovascular disease, autoimmune disorders, and pediatric medicine, consistently bringing the perspective of a drug developer to collaborative pre-competitive research. They focus on improving how medicines are evaluated, how clinical data is shared, and how translational safety is assessed from preclinical models to patients.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), IRIS focused heavily on foundational drug development challenges: adaptive regulatory pathways (ADAPT-SMART), translational safety science (TransQST, eTRANSAFE), and disease mechanism research in atherosclerosis and chronic inflammation (REPROGRAM). From 2019 onward, their involvement shifted decisively toward clinical trial infrastructure, patient-centric platforms, and health data governance — reflected in projects like EU-PEARL, EHDEN, BIGPICTURE, and c4c. This evolution mirrors the pharmaceutical industry's broader move from molecule-focused R&D toward data-driven, platform-based clinical development.

IRIS is moving toward data infrastructure and platform trial operations, making them a strong partner for projects requiring pharma-industry input on real-world evidence and federated health data systems.

How they like to work

IRIS operates exclusively as a consortium participant — they have never coordinated an H2020 project, which is typical for large pharma in IMI/public-private partnerships where they contribute industry data, expertise, and in-kind resources rather than leading administratively. With 294 unique partners across 27 countries, they are deeply embedded in Europe's health research network and consistently join large-scale, multi-partner consortia (many of their projects involve 30+ organizations). This makes them an accessible and experienced partner, but one that expects well-structured consortium governance.

IRIS has collaborated with 294 unique organizations across 27 countries, giving them one of the broadest partnership networks in European pharmaceutical research. Their connections span academic medical centers, regulatory bodies, patient organizations, and other pharma companies — a reflection of the large IMI-style consortia they consistently join.

What sets them apart

As the research arm of an independent (non-listed) pharmaceutical company, IRIS brings genuine industry drug development data and processes to collaborative projects without the bureaucratic constraints of publicly traded big pharma. Their 16-project portfolio covers the full drug lifecycle — from preclinical safety to clinical trials to post-market data — making them unusually versatile as a pharma-industry partner. For consortium builders, they offer a credible industry voice that satisfies IMI co-funding requirements while being more agile than the largest multinationals.

Highlights from their portfolio

• eTRANSAFE
  Flagship IMI project on translational safety data integration — directly aligned with IRIS's core mission of improving drug safety assessment across preclinical and clinical phases.
• EU-PEARL
  Major platform trial initiative covering depression, tuberculosis, and liver disease — represents IRIS's strategic shift toward innovative trial design and patient-centric methodologies.
• BIGPICTURE
  Europe's largest digital pathology repository project (running to 2027), positioning IRIS at the intersection of AI and pharmaceutical pathology — their most forward-looking investment.